Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
|
|
Loxo Oncology, Inc. (LOXO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/01/2019 |
GN
| Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction |
| 01/15/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of Loxo Oncology, Inc. to Eli Lilly and Company is Fair to Shareholders |
| 01/09/2019 |
GN
| MERGER ALERT – BDMS, LOXO and MB: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies |
| 01/07/2019 |
GN
| Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Loxo Oncology, Inc. (LOXO) on Behalf of Stockholders and Encourages LOXO Investors to Contact the Firm |
| 01/07/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Loxo Oncology, Inc. to Eli Lilly and Company is Fair to Shareholders |
| 01/07/2019 |
GN
| Lilly Announces Agreement To Acquire Loxo Oncology |
| 12/21/2018 |
GN
| Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305 |
| 11/29/2018 |
GN
| Recent Analysis Shows Mid-America Apartment Communities, Loxo Oncology, Arista Networks, ADT, Welltower, and First Majestic Silver Market Influences ??? Renewed Outlook, Key Drivers of Growth |
| 11/26/2018 |
GN
| FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2) |
| 11/08/2018 |
GN
| Loxo Oncology Reports Third Quarter 2018 Financial Results |
| 11/06/2018 |
GN
| Loxo Oncology to Participate in Upcoming Investor Conferences |
| 11/01/2018 |
GN
| Loxo Oncology to Announce Third Quarter 2018 Financial Results |
| 10/21/2018 |
GN
| Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress |
| 10/15/2018 |
GN
| Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer |
| 10/09/2018 |
GN
| Loxo Oncology Announces Details for Data Presentations at the European Society for Medical Oncology 2018 Congress |
| 10/06/2018 |
GN
| Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET-Mutant Medullary Thyroid Cancer and RET Fusion-Positive Thyroid Cancer from LIBRETTO-001 at the 88th Annual Meeting of the American Thyroid Association |
| 09/25/2018 |
GN
| Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer from LIBRETTO-001 at the IASLC 19th World Conference on Lung Cancer |
| 09/05/2018 |
GN
| Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 |
| 08/29/2018 |
GN
| Loxo Oncology to Present at Upcoming Investor Conferences |
| 08/27/2018 |
GN
| Loxo Oncology Announces Submission of European Marketing Authorization Application for Larotrectinib |
| 08/10/2018 |
GN
| Loxo Oncology Announces Accepted Abstracts at the IASLC 19th World Conference on Lung Cancer |
| 08/09/2018 |
GN
| Loxo Oncology Reports Second Quarter 2018 Financial Results |
| 08/02/2018 |
GN
| Loxo Oncology to Announce Second Quarter 2018 Financial Results |
| 06/07/2018 |
GN
| New Research Coverage Highlights Durect, Credit Suisse Group, Obsidian Energy, TransCanada, Golden Star Resources, and Loxo Oncology — Consolidated Revenues, Company Growth, and Expectations for 2018 |
| 06/02/2018 |
GN
| Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual Meeting |
| 05/29/2018 |
GN
| FDA Accepts Larotrectinib New Drug Application and Grants Priority Review |
| 05/16/2018 |
GN
| Loxo Oncology Announces Details of LOXO-292 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting |
| 05/08/2018 |
GN
| Loxo Oncology Reports First Quarter 2018 Financial Results |
| 05/07/2018 |
GN
| Loxo Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 05/01/2018 |
GN
| Loxo Oncology to Announce First Quarter 2018 Financial Results |
| 04/12/2018 |
GN
| Investor Expectations to Drive Momentum within Loxo Oncology, Kinross Gold, Marlin Business Services, lululemon athletica inc, LG Display Co., and QIWI — Discovering Underlying Factors of Influence |
| 04/10/2018 |
GN
| Loxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics |
| 04/04/2018 |
GN
| Loxo Oncology Announces Acceptance of LOXO-292 Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting |
| 03/26/2018 |
GN
| Loxo Oncology Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancer |
|
|
|